Lucira Health (LHDX) Biggest Gainer ($0.13 to $0.87) 💪✅🚀
Lucira Health went public in February 2021, raising $153 million in an IPO.
The firm is developing various infectious disease testing kits.
Its first kit, for COVID-19, has produced rapidly growing revenue since launch.
LHDX is still seeking to diversify its revenue streams, so until we gain further visibility into that progress, I'm on Hold for the stock.
LHDX Signals & Forecast
There are few to no technical positive signals at the moment. The Lucira Health, Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.129 and $0.334. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 22, 2022, and so far it has fallen -76.85%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Support, Risk & Stop-loss for Lucira Health, Inc. stock
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
$0.111 $0.120
This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.0210 between high and low, or 19.44%. For the last week the stock has had daily average volatility of 26.26%.
Lucira Health, Inc. is oversold on RSI14 (8). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (LHDX) For The Upcoming Trading Day Of Tuesday 3rd
For the upcoming trading day on Tuesday, 3rd we expect Lucira Health, Inc. to open at $0.116, and during the day (based on 14 day Average True Range), to move between $0.0622 and $0.160, which gives a possible trading interval of +/-$0.0489 (+/-44.04%) up or down from last closing price. If Lucira Health, Inc. takes out the full calculated possible swing range there will be an estimated 88.07% move between the lowest and the highest trading price during the day.
With no support below and resistance from accumulated volume @ $0.0089 (8.01%) our system find the risk reward not very attractive.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
$Lucira Health, Inc.(LHDX)$
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Who are Lucira Health's (LHDX) competitors?
Other companies in Lucira Health’s space includes: NeuroPace (NASDAQ:NPCE), Precision Optics Corp (NASDAQ:POCI), ENDRA Life Sciences (NASDAQ:NDRA), LENSAR (NASDAQ:LNSR) and Venus Concept (NASDAQ:VERO).
$NeuroPace Inc.(NPCE)$
$PRECISION OPTICS INC(MASS)(POCI)$
$ENDRA Life Sciences Inc(NDRA)$
$LENSAR Inc(LNSR)$
$Venus Concept Inc.(VERO)$
$Lucira Health, Inc.(LHDX)$
Lucira Health, Inc.
LHDX
+434.6%
+ Free Alerts
shares are surging higher on Tuesday after the company announced it submitted an Emergency Use Authorization application to the FDA for over-the-counter use of its COVID-19 & Flu test.
What happened: Today, Lucira announced that it submitted an Emergency Use Authorization (EUA) application for its at-home molecular COVID-19 & Flu test kits. The company first received EUA for point-of-care use in a healthcare setting in November 2022.
The company’s kits test for COVID-19 and influenza, which the company noted, have similar symptoms but different treatments that are most effective early in an infection. The test aims to differentiate between the two viruses quickly.
$Lucira Health, Inc.(LHDX)$
Lucira Health, Inc.
LHDX
+434.6%
+ Free Alerts
shares are surging higher on Tuesday after the company announced it submitted an Emergency Use Authorization application to the FDA for over-the-counter use of its COVID-19 & Flu test.
What happened: Today, Lucira announced that it submitted an Emergency Use Authorization (EUA) application for its at-home molecular COVID-19 & Flu test kits. The company first received EUA for point-of-care use in a healthcare setting in November 2022.
The company’s kits test for COVID-19 and influenza, which the company noted, have similar symptoms but different treatments that are most effective early in an infection. The test aims to differentiate between the two viruses quickly.
Pre-market trading may touch $0.38 to swing to $0.7 wow what are big swing
Ok
👍👍👍